Cartesian Therapeutics (RNAC) News Today $15.92 -0.02 (-0.13%) As of 03/25/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Timothy Springer Spends US$1.4m On Cartesian Therapeutics StockMarch 23 at 9:15 AM | finance.yahoo.comResearch Analysts Issue Forecasts for RNAC FY2025 EarningsMarch 21, 2025 | americanbankingnews.comAnalysts Set Expectations for RNAC FY2025 EarningsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for Cartesian Therapeutics in a report issued on Monday, March 17th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($3.65) per share for the year. CaMarch 20, 2025 | marketbeat.comOppenheimer Reaffirms Their Hold Rating on Cartesian Therapeutics (RNAC)March 17, 2025 | markets.businessinsider.comErste Asset Management GmbH Has $3.26 Million Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Erste Asset Management GmbH lowered its stake in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 93.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 173,566 shares of the company's stock after selling 2,527,000 shares during the peMarch 16, 2025 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLCMarch 16, 2025 | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) Given New $40.00 Price Target at HC WainwrightMarch 16, 2025 | americanbankingnews.comCartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 16, 2025 | finanznachrichten.deHC Wainwright Issues Pessimistic Forecast for Cartesian Therapeutics (NASDAQ:RNAC) Stock PriceHC Wainwright reduced their target price on Cartesian Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a report on Friday.March 15, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)Needham & Company LLC restated a "buy" rating and set a $41.00 price objective on shares of Cartesian Therapeutics in a research note on Thursday.March 14, 2025 | marketbeat.comCartesian Therapeutics Advances mRNA Therapy PipelineMarch 14, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and ProQR (PRQR)March 14, 2025 | markets.businessinsider.comCartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 13, 2025 | finance.yahoo.comTD Cowen Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)March 13, 2025 | markets.businessinsider.comCartesian Therapeutics announces employment inducement grantMarch 6, 2025 | markets.businessinsider.comCartesian Therapeutics Announces New Employment Inducement GrantMarch 6, 2025 | globenewswire.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and eight have assigned a buy ratingMarch 6, 2025 | marketbeat.comCartesian Therapeutics (RNAC) Projected to Post Earnings on ThursdayCartesian Therapeutics (NASDAQ:RNAC) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comCartesian Therapeutics to Participate in Upcoming Investor ConferencesFebruary 18, 2025 | globenewswire.comFY2024 Earnings Forecast for RNAC Issued By Leerink PartnrsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Cartesian Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will postFebruary 10, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from AnalystsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has earned an average rating of "Moderate Buy" from the ten brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation toFebruary 9, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for RNAC FY2029 Earnings?Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Cartesian Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will poFebruary 7, 2025 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsFebruary 6, 2025 | globenewswire.comPromising Developments and Strategic Expansion Bolster Buy Rating for Cartesian TherapeuticsJanuary 29, 2025 | markets.businessinsider.comStrong Outlook for Cartesian Therapeutics: FDA SPA Agreement and Positive Phase 2b Results Boost Confidence in Descartes-08January 28, 2025 | markets.businessinsider.comBuy Rating for Cartesian Therapeutics: Promising Phase 3 Prospects for Descartes-08 in Treating Myasthenia GravisJanuary 28, 2025 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $45.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday.January 28, 2025 | marketbeat.comCartesian Therapeutics announces FDA SPA agreement for Phase 3 AURORA trialJanuary 27, 2025 | markets.businessinsider.comNeedham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)Needham & Company LLC reissued a "buy" rating and set a $41.00 price target on shares of Cartesian Therapeutics in a research note on Monday.January 27, 2025 | marketbeat.comCartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia GravisJanuary 27, 2025 | globenewswire.comCartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA TherapiesJanuary 17, 2025 | seekingalpha.comPromising Developments and Strategic Milestones Drive Buy Rating for Cartesian TherapeuticsJanuary 15, 2025 | markets.businessinsider.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten brokerages that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have issuedJanuary 15, 2025 | marketbeat.comCartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune DiseasesJanuary 13, 2025 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $41.00 price target on shares of Cartesian Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comCartesian Therapeutics announces employment inducement grantsJanuary 8, 2025 | markets.businessinsider.comMilos Miljkovic Sells 932 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) StockJanuary 8, 2025 | insidertrades.comMilos Miljkovic Sells 932 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) insider Milos Miljkovic sold 932 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $16.72, for a total transaction of $15,583.04. Following the transaction, the insider now directly owns 36,341 shares in the company, valued at approximately $607,621.52. This represents a 2.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.January 7, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 SharesCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) insider Milos Miljkovic sold 948 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $16.83, for a total value of $15,954.84. Following the sale, the insider now owns 35,393 shares in the company, valued at approximately $595,664.19. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 7, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $40,412.24 in StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CTO Metin Kurtoglu sold 2,417 shares of the company's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $16.72, for a total transaction of $40,412.24. Following the transaction, the chief technology officer now owns 64,716 shares of the company's stock, valued at $1,082,051.52. This represents a 3.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.January 7, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 SharesCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CTO Metin Kurtoglu sold 2,458 shares of Cartesian Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $16.83, for a total value of $41,368.14. Following the completion of the transaction, the chief technology officer now directly owns 62,258 shares of the company's stock, valued at $1,047,802.14. This represents a 3.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 7, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Sells $66,227.92 in StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CFO Blaine Davis sold 3,961 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $16.72, for a total value of $66,227.92. Following the completion of the transaction, the chief financial officer now directly owns 98,839 shares of the company's stock, valued at approximately $1,652,588.08. The trade was a 3.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.January 7, 2025 | marketbeat.comInsider Selling: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Sells 4,028 Shares of StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CFO Blaine Davis sold 4,028 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $16.83, for a total value of $67,791.24. Following the completion of the transaction, the chief financial officer now owns 94,811 shares of the company's stock, valued at $1,595,669.13. The trade was a 4.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.January 7, 2025 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsJanuary 7, 2025 | globenewswire.comCartesian Therapeutics (RNAC) Has a New Rating from BTIGDecember 30, 2024 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Stock Price Up 7.2% - Time to Buy?Cartesian Therapeutics (NASDAQ:RNAC) Trading Up 7.2% - Here's What HappenedDecember 26, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by BrokeragesCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have given a buy ratingDecember 21, 2024 | marketbeat.comCartesian Therapeutics initiated with a Buy at BTIGDecember 20, 2024 | markets.businessinsider.comBTIG Initiates Coverage of Cartesian Therapeutics (RNAC) with Buy RecommendationDecember 20, 2024 | msn.comBTIG Research Begins Coverage on Cartesian Therapeutics (NASDAQ:RNAC)BTIG Research assumed coverage on shares of Cartesian Therapeutics in a report on Thursday. They issued a "buy" rating and a $42.00 price target on the stock.December 19, 2024 | marketbeat.com Remove Ads Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address RNAC Media Mentions By Week RNAC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAC News Sentiment▼1.080.77▲Average Medical News Sentiment RNAC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAC Articles This Week▼73▲RNAC Articles Average Week Remove Ads Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANIP News Today DYN News Today INDV News Today AMPH News Today ARDX News Today EVO News Today ETNB News Today OCUL News Today GPCR News Today IOVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAC) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNAC Stock Free RNAC Stock Alerts